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Non-Specialty Specialty
June 2012
Drug Name: Cariprazine
Manufacturer: Forest & Gedeon Richter 
Indication: Schizophrenia
Formulation: Oral capsule
Phase III
Drug Name: Buprenorphine
Manufacturer: Titan Pharmaceuticals
Indication: Opioid addiction
Formulation: SC implant
Cariprazine, a potent dopamine D3/D2 receptor 
partial agonist with a preference for D3, is an 
antipsychotic being studied for the treatment of 
acute exacerbations of schizophrenia. 
In a Phase III (N=617), double-blind, multicenter, 
fixed-dose, six-week trial, cariprazine was compared 
to placebo in patients with an acute exacerbation of 
schizophrenia. Treatment with cariprazine resulted in 
a greater improvement in the Positive and Negative 
Syndrome Scale (PANSS) total score, from baseline 
to week six, relative to placebo (3 mg per day: -6.0, 
P=0.0044, 6 mg per day: -8.8, P<0.0001). In a similarly 
designed Phase III (N=446), six-week, fixed-flexible 
dose study, treatment with cariprazine resulted in a 
greater improvement in the PANSS total score relative 
to placebo (3 mg to 6 mg per day: -6.8, P=0.0029, 
6 mg to 9 mg per day: -9.9, P<0.0001). Cariprazine 
has also shown efficacy in patients with acute mania 
associated with bipolar 1 disorder in Phase III trials 
and is being investigated in bipolar depression and as 
adjunctive treatment for Major Depressive Disorder.
Similar to other atypical antipsychotics, 
cariprazine may have a safer side effect profile due 
to decreased affinity for serotonergic, histaminergic, 
muscarinic, and adrenergic receptors. Cariprazine has 
exhibited increased antagonism at the D3 receptor, 
which may be associated with enhanced cognition 
known to improve psychosocial functioning in patients 
with schizophrenia — offering a potential advantage 
over Abilify® (aripiprazole). An NDA submission for 
schizophrenia and bipolar mania is planned for 2012. 
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Probuphine™ is a subcutaneous (SC) implant of 
buprenorphine being studied for the treatment of 
opioid addiction. Designed to slowly release constant 
levels of buprenorphine over six months, it has a rate 
of release similar to intravenous (IV) infusion.  
A Phase III (N=163), randomized, double-blind 
trial compared the buprenorphine SC implant to 
placebo for the treatment of opioid addiction. The 
primary endpoint was the proportion of urine samples 
per patient that were negative for illicit opioids 
during the first 16 weeks of therapy. Treatment 
with the buprenorphine SC implant resulted in a 
greater proportion of negative urine samples over 
placebo (40.4 versus 28.3 percent, P=0.04). A second 
Phase III (N=287), randomized trial supported the 
superiority of buprenorphine SC implant over placebo 
(P<0.0001). This trial also demonstrated the non-
inferiority of buprenorphine SC implant to Suboxone® 
(buprenorphine/naloxone) tablets as measured by the 
proportion of opioid-negative urine samples over six 
months (31 versus 33 percent, 95 percent CI of the 
mean difference -10.8 to 5.9). 
By delivering constant levels of buprenorphine, 
this SC implant may result in less variability in 
buprenorphine levels when compared to the plasma 
peaks and troughs associated with sublingual tablets. 
As a result, buprenorphine SC implants may increase 
patient compliance and reduce cravings that occur 
as a result of fluctuations in buprenorphine levels. A 
new drug application (NDA) for the buprenorphine SC 
implant is expected to be submitted to the FDA in the 
third quarter of 2012.
Phase III
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Drug Name: Daclatasvir
Manufacturer: Bristol-Myers Squibb
Indication: Chronic hepatitis C
Formulation: Oral tablet
Phase III
Drug Name: Hydrocodone
Manufacturer: Zogenix
Indication: Chronic pain                  
Formulation: ER oral capsule
Drug Name: Quad
Manufacturer: Gilead Sciences
Indication: HIV-1 infection
Formulation: Oral tablet
NDA
Daclatasvir is being studied for the 
treatment of chronic hepatitis C virus 
(HCV). This agent is a highly selective 
HCV NS5A replication complex inhibitor 
that interferes with viral replication and 
assembly.
Three groups were included in a 
Phase II (N=43), open-label trial: patients 
with chronic HCV genotype 1b with a prior 
null response to peginterferon alfa (alfa) 
plus ribavirin (RBV), patients considered 
ineligible for alfa plus RBV, or those with 
prior intolerance to alfa plus RBV. All were 
treated with daclatasvir 60 mg once daily 
and asunaprevir, an investigational NS3 
protease inhibitor (PI), 200 mg twice daily 
for 24 weeks. Sustained virologic response 
(SVR) 12 weeks post-treatment was 
achieved in 77 percent of patients (P-value 
not reported). At 24 weeks post-treatment, 
100 percent of patients who achieved SVR 
at 12 weeks maintained undetectable viral 
loads (P-value not reported). Common 
treatment-related adverse events included 
headache, nasopharyngitis, elevated liver 
enzymes, diarrhea, and fever. Currently, 
daclatasvir is in Phase III studies in 
treatment-naïve patients as well as in a 
head-to-head comparison with telaprevir.
Daclatasvir may be an oral option 
that has a unique mechanism of action 
for the treatment of HCV. When used in 
combination with a PI, it may represent an 
alternative for difficult-to-treat patients 
with HCV genotype 1, the most prevalent 
genotype, including null responders and 
those intolerant to standard therapy.
Quad is under FDA review for the 
treatment of human immunodeficiency 
virus type 1 (HIV-1) infection. It is a once-
daily formulation of the investigational 
integrase inhibitor elvitegravir (EVG), 
combined with emtricitabine (FTC), 
tenofovir (TDF), and cobicistat (COBI), a 
boosting agent with no anti-HIV activity.
In a Phase III (N=700), double-blind, 
trial, treatment-naïve adults with HIV-
1 were randomized to EVG/COBI/FTC/
TDF or Atripla® (efavirenz [EFV]/FTC/
TDF). Results showed a similar proportion 
of patients achieved a viral load of less 
than 50 copies/mL at week 48 in both 
the EVG/COBI/FTC/TDF and the EFV/
FTC/TDF groups (88 versus 84 percent, 95 
percent CI for the difference -1.6 to 8.8), 
meeting the pre-defined criterion for non-
inferiority. In a similarly designed Phase 
III (N=708), double-blind trial, a similar 
proportion of patients achieved a viral load 
of less than 50 copies/mL at week 48 who 
received EVG/COBI/FTC/TDF or Reyataz® 
(atazanavir [AZT]) 300 mg boosted by 
Norvir® (ritonavir) plus Truvada® (FTC/
TDF) (90 versus 87 percent, 95 percent 
CI for the difference -1.9 to 7.8) again, 
meeting the pre-defined criterion for 
non-inferiority. Nausea was more common, 
while CNS side effects and rash were 
reduced with EVG/COBI/FTC/TDF versus 
EFV/FTC/TDF. 
If approved, EVG/COBI/FTC/TDF may 
offer the advantage of once-daily dosing, 
and fewer CNS side effects and rash 
compared with EFV/FTC/TDF, the only 
single tablet once-daily regimen currently 
available. An FDA decision is expected on 
Aug. 27, 2012.
Zohydro™ is an oral, extended-
release (ER) formulation of hydrocodone 
being developed for the treatment of 
moderate to severe chronic pain in 
patients requiring around-the-clock opioid 
therapy. 
In a Phase III, double-blind trial, over 
300 opioid-experienced adult patients 
with moderate to severe chronic low 
back pain not adequately relieved by 
their existing therapy were randomized 
to receive hydrocodone ER 20 mg to 100 
mg or placebo every 12 hours. Treatment 
with hydrocodone ER resulted in improved 
pain relief from baseline to week 12 as 
measured by the average 24-hour pain 
intensity ratings, the study’s primary 
endpoint, when compared to placebo 
(P=0.008). A greater proportion of patients 
who received hydrocodone ER experienced 
at least a 30 percent or at least a 50 
percent improvement in pain intensity 
compared to placebo (68 versus 31 percent 
and 48 versus 23 percent, respectively, 
P<0.001 for both). Common adverse 
events occurring in more than 5 percent 
of patients treated with hydrocodone 
ER included constipation, nausea, and 
urinary tract infections.
If approved, hydrocodone ER may 
become the first hydrocodone product 
without acetaminophen, reducing the risk 
of liver toxicity. Hydrocodone ER may also 
provide consistent pain relief compared 
to currently available immediate release 
opioids. An NDA was submitted to the FDA 
on May 2, 2012. 
NDA
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Drug Name: Tivozanib
Manufacturer: AVEO Pharmaceuticals
Indication: Renal cell carcinoma 
Formulation: Oral capsule
Phase III
Drug Name: Teduglutide
Manufacturer: NPS Pharmaceuticals
Indication: Short bowel syndrome
Formulation: SC injection
NDA
Drug Name: Tedizolid
Manufacturer: Trius Therapeutics
Indication: Gram positive infections
Formulation: IV/oral tablet
Phase III
Tivozanib, a tyrosine kinase inhibitor 
selective for vascular endothelial growth 
factor (VEGF) receptors -1, -2, and -3, 
is being studied for the treatment of 
advanced renal cell carcinoma (RCC). 
Inhibition of VEGF receptors may prevent 
cancer cell survival and angiogenesis.
In a Phase III (N=517), randomized, 
open-label, multicenter trial, four-week 
cycles of oral tivozanib 1.5 mg daily for 
three weeks, followed by one week off, 
was compared to continuous four-week 
cycles of oral Nexavar® (sorafenib) 400 
mg twice daily in patients with a history 
of no more than one prior systemic 
therapy for advanced RCC. After 24 
months, there was greater improvement 
in median progression-free survival 
in patients who received tivozanib 
compared to sorafenib in the overall 
study population (11.9 versus 9.1 months, 
P-value not reported) and the treatment-
naïve subgroup, representing 70 percent 
of all patients (12.7 versus 9.1 months, 
P-value not reported). Common adverse 
events included reversible hypertension 
and dysphonia, while off-target toxicities, 
such as mucositis, fatigue, and hand-foot 
syndrome, which are commonly associated 
with other targeted VEGF therapies, were 
low in patients treated with tivozanib.
Given its selectivity for VEGF 
receptors, tivozanib may offer a safer 
alternative compared to first-line VEGF 
inhibitors such as Sutent® (sunitinib) and 
Votrient™ (pazopanib). This may allow 
tivozanib to be combined with standard 
chemotherapy, increasing its use in other 
forms of cancer. An NDA submission is 
planned for the third quarter of 2012.
Tedizolid, a second generation 
oxazolidinone, is in development as an 
IV and oral treatment for serious gram 
positive infections, including those caused 
by methicillin-resistant Staphylococcus 
aureus (MRSA). By binding to the 50S 
ribosome, tedizolid inhibits bacterial 
protein synthesis.
 A Phase III (N=667), randomized, 
double-blind trial, evaluated the safety 
and efficacy of oral tedizolid, 200 mg once 
daily for six days followed by four days of 
placebo, versus oral Zyvox® (linezolid), 
600 mg twice daily for 10 days, in patients 
with acute bacterial skin and skin structure 
infections. Cessation of infection spread 
and absence of fever at 48 to 72 hours 
was achieved by 79.5 and 79.4 percent 
of patients in the tedizolid and linezolid 
groups, respectively, meeting the study’s 
non-inferiority criteria (P-value not 
reported). Treatment-related adverse 
events were greater in patients treated 
with linezolid compared to tedizolid 
(31 versus 24.2 percent, respectively, 
P-value not reported). Gastrointestinal 
(GI) events, the most commonly reported 
adverse event, ocurred in fewer patients 
in the tedizolid group than in the linezolid 
group (16.3 versus 25.4 percent, P=0.004). 
Tedizolid offers a shorter treatment 
duration, fewer GI side effects, and 
once-daily dosing compared to twice-daily 
linezolid. Tedizolid may represent a new 
option for difficult-to-treat infections as 
it has also demonstrated activity against 
linezolid-resistant organisms. 
Gattex® (teduglutide), a recombinant 
analog of human glucagon-like peptide 2 
(GLP-2), is currently under FDA review for 
the treatment of short bowel syndrome 
(SBS). Repeated administration of GLP-2 
promotes expansion and growth of the 
intestinal mucosa and reduces enterocyte 
apoptosis.
In STEPS, a Phase III (N=86), double-
blind trial, the percentage of patients who 
achieved at least a 20 percent reduction 
in weekly parenteral nutrition (PN) volume 
compared to baseline at week 20 and 
maintained that response at week 24 was 
higher with SC teduglutide 0.05 mg/kg 
daily compared to placebo in adults with 
SBS (63 versus 30 percent, respectively, 
P=0.002). In STEPS 2 (N=88), an open-
label, extension of STEPS, 91 percent 
of patients treated with teduglutide 
maintained reductions in PN and IV fluid 
volume, defined as a 20 to 100 percent 
reduction from baseline, after 12 months. 
Additionally, after 12 months of treatment 
with teduglutide, 24 percent of patients 
needed at least three fewer days of PN or 
IV fluids per week, and seven patients no 
longer required PN or IV fluid (P-value not 
reported). The most commonly reported 
adverse events were GI-related.
Through intestinal rehabilitation, 
teduglutide may improve the integrity and 
function of the existing intestine, and may 
also reduce or eliminate the need for PN 
or IV fluids, which is often associated with 
complications. An FDA decision is expected 
Sept. 30, 2012. 
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Incivek® (telaprevir)
In a Phase II (N=62) trial, adults coinfected with HCV 
genotype 1 and HIV were randomized to receive 
telaprevir, Pegasys® (peginterferon alfa-2a) and 
Copegus® (ribavirin), or peginterferon alfa-2a and 
ribavirin alone. All patients were naïve to HCV 
treatment and either not receiving antiretroviral 
therapy (ART) or taking an AZT- or EFV/FTC/TDF-
based ART regimen. Interim results showed that 
sustained virologic response (SVR) 12 weeks after 
completing treatment was achieved in 74 percent of 
patients receiving add-on telaprevir versus 45 percent 
of those receiving ribavirin and peginterferon alfa-2a 
alone (P-value not reported).
Information available at www.vertex.com
Victrelis® (boceprevir)
In a Phase IIb (N=100) trial, adults coinfected with 
HCV genotype 1 and stable HIV, who were HCV 
treatment-naïve and on ART, were randomized to 
boceprevir 800 mg three times daily with weekly PEG-
Intron™ (peginterferon alfa-2b) plus daily ribavirin 
or peginterferon alfa-2b plus ribavirin alone. Interim 
results showed that SVR at 12 weeks after ending 
treatment was achieved in 60.7 percent of patients 
treated with add-on boceprevir and 26.5 percent of 
those treated with peginterferon alfa-2b plus ribavirin 
alone (P-value not reported). 
Information available at www.merck.com
•  Lescol®  XL  (fluvastatin)
     6/2012
•  Clarinex®/Clarinex-D®                              
    (desloratadine/desloratadine                
     & pseudoephedrine) 
     7/2012
•  TriCor® (fenofibrate)
     7/2012   
•  Actos® (pioglitazone)  
     8/2012
•  Singulair® (montelukast) 
     8/2012
•  Xopenex®  (levalbuterol)†
     8/2012
•  Detrol® (tolterodine)
     9/2012
•  Diovan®/Diovan HCT® (valsartan/        
     valsartan & hydrochlorothiazide)
     9/2012
 
Apixaban (Eliquis®)
On Feb. 29, 2012, Bristol-Myers Squibb and 
Pfizer announced that the FDA extended the 
action date by three months for the NDA for 
apixaban, an oral direct Factor Xa inhibitor 
in development for the prevention of stroke 
and systemic embolism in patients with atrial 
fibrillation. After the initial NDA was filed, the 
manufacturers of apixaban submitted additional 
information that was considered a major 
amendment to the application requiring more 
time for FDA review. Currently, there are no 
plans for the FDA advisory committee to review 
this NDA. An FDA decision is expected on June 
28, 2012.
Dapagliflozin
On Jan. 19, 2012, the FDA issued a complete 
response letter (CRL) to AstraZeneca and 
Bristol-Myers Squibb regarding the NDA for 
dapagliflozin for the treatment of adults with 
type 2 diabetes. Additional clinical data was 
requested to better assess the benefit-risk 
profile of dapagliflozin. The CRL came after the 
Endocrinologic and Metabolic Drugs Advisory 
Committee previously voted against approval 
in July 2011 due to safety concerns regarding 
increased risk of liver toxicity and breast and 
bladder cancers. The manufacturers have 
stated they will work closely with the FDA to 
determine appropriate next steps for the NDA.
Ridaforolimus (Taltorvic®)
On June 5, 2012, the FDA issued a CRL regarding 
the NDA for ridaforolimus, an oral inhibitor 
of mammalian target of rapamycin, seeking 
approval as maintenance treatment for 
metastatic soft-tissue or bone sarcoma. The 
FDA declined approval for this agent, requesting 
that additional clinical trials be conducted to 
further evaluate safety and efficacy. The FDA’s 
Oncologic Drugs Advisory Committee previously 
voted 13 to 1 against approval, citing concern 
that the increase in progression-free survival 
was small compared to placebo, given the side 
effect profile of ridaforolimus, which includes 
infection, rash, and potential kidney damage. 
*Dates are estimates, current as of 6/15/12, and are subject to change due to any patent litigation or additional patents.
•    Revatio® (sildenafil)  
       9/2012
•    Lidoderm® (lidocaine  patch) 
       11/2012
•    Actoplus Met® (pioglitazone & 
       metformin) 
  12/2012
•    Atacand®/Atacand HCT®                            
      (candesartan/candesartan &     
       hydrochlorothiazide) 
       12/2012
•    Evoxac® (cevimeline)    
       12/2012
 •   Maxalt®/Maxalt-MLT®   
 (rizatriptan)  
  12/2012
•    Opana®  ER (oxymorphone) 
  1/2013
•    Zometa®  (zoledronic acid) 
  3/2013
†Levalbuterol inhalation solution, not hydrofluoroalkane
 CNS
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Agents in Clinical Development
Pipeline Research
Phase I - 33%
Phase II - 37%
Phase III - 21%
NDA/BLA - 9%
Oncology - 16%
Infectious Disease - 15%
CNS - 12%
Pain and 
Inflammation - 9%
Cardiology - 8%
Metabolic - 6%
Respiratory - 5%
Other - 29% Pfizer
Mild to moderately   
active UC
Opioid dependence
Weight management
Arena
 Pharmaceuticals, 
Eisai
Table Abbreviations: BLA = biologics license application, CML = chronic 
myeloid leukemia, HoFH = homozygous familial hypercholesterolemia,                 
IV = intravenous, NDA = new drug application, PDUFA = prescription 
drug user fee act, rhPTH = recombinant human parathyroid hormone,                         
SC = subcutaneous, UC = ulcerative colitis
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A/
BL
A Phase III
Pha
se I
I
On
co
lo
gy
CNSPain/Infl.
Ca
rd
io
.
Me
ta
bo
licResp.
Inf. Dis
ease
Phase I
Other
Lorcaserin PDUFA date 6/27/2012
Apixaban (Eliquis®) Bristol-Myers Squibb, 
Pfizer
Atrial fibrillation
AMR101 Amarin
 
Very high
triglycerides
Delayed-release low-dose 
prednisone (Lodotra®)
Horizon Pharma Rheumatoid arthritis PDUFA date 7/26/2012
Budesonide (Uceris™) PDUFA date 10/16/2012
Tofacitinib* FDA decision expected 8/2012
IPX066 Impax                   
Pharmaceuticals
Idiopathic Parkinson’s 
disease
PDUFA date 10/21/2012
Treprostinil
United                 
Therapeutics
Pulmonary arterial 
hypertension
PDUFA date 10/27/2012
CRTX 080
Cornerstone         
Therapeutics
           Hyponatremia
Lomitapide
Aegerion               
Pharmaceuticals HoFH
PDUFA date 12/29/2012
Carfilzomib (IV)*
Onyx                     
Pharmaceuticals
PDUFA date 7/27/2012
Mipomersen             
(Kynamro™) (SC)*
HoFH PDUFA date 1/29/2013
Ponatinib* CML NDA submission planned                  
for third quarter of 2012
rhPTH                              
(Natpara™) (SC)
NPS                     
Pharmaceuticals
Hypoparathyroidism
BLA submission planned                       
for second half of 2012
Antares Pharma Rheumatoid arthritis
NDA submission planned                    
for first half of 2013
BioDelivery Sciences 
International
NDA submission planned                                 
for first half of 2013
PDUFA date 6/28/2012
PDUFA date 7/26/2012
Relapsed and refractory 
multiple myeloma
Rheumatoid arthritis
Santarus
 Ariad                        
Pharmaceuticals          
Methotrexate          
(Vibex™) (SC)
BEMA® Buprenorphine/
naloxone 
PDUFA date 10/29/2012
Genzyme,                         
Isis Pharmaceuticals
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Who We Are and What We Do
The University of Massachusetts Medical School’s Clinical Pharmacy Services is a comprehensive 
prescription drug management program developed in 1999 as part of the Medical School’s Commonwealth 
Medicine division, primarily to provide drug utilization review for Massachusetts Medicaid.  Today, we bring    
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managed care-related clinical pharmacy functions including, but not limited to, evidence-based formulary 
support, pharmacoeconomic modeling, drug utilization review, medication therapy management, clinical 
call center support, and provider/patient education. 
PIPELINE TRxENDS is an educational resource produced twice yearly to deliver critical information at the 
highest level of quality to our clients.  We hope that you find this resource of value, and we welcome your 
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